10-Q: BD Reports Strong Q3 Revenue, Announces Spin-Off Plan

Becton, Dickinson and Company reported a 10.4% revenue increase in Q3 2025, alongside a strategic plan to combine its Biosciences and Diagnostic Solutions business with Waters Corporation.

Summary

• Total revenues for the three months ended June 30, 2025, increased by 10.4% to $5.509 billion, compared to $4.990 billion in the prior-year period.
• Operating income for Q3 2025 was $882 million, a significant increase from $602 million in Q3 2024.
• Net income for Q3 2025 rose to $574 million from $487 million in Q3 2024, an 17.9% increase.
• Diluted Earnings per Share (EPS) for Q3 2025 was $2.00, up from $1.68 in Q3 2024.
• For the nine months ended June 30, 2025, total revenues increased by 8.2% to $15.949 billion.
• Net income for the nine months ended June 30, 2025, decreased by 9.2% to $1.185 billion, primarily due to higher 'specified items' and increased interest expense.
• Diluted EPS for the nine months ended June 30, 2025, was $4.10, down from $4.49 in the prior-year period.
• The company announced a definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation in a Reverse Morris Trust transaction, expected to close around the end of calendar year 2026 Q1.
• BD is expected to receive a cash distribution of approximately $4 billion from the Waters transaction, and Waters is expected to assume approximately $4 billion of incremental debt.
• The transaction is anticipated to be generally tax-free for U.S. federal income tax purposes to BD and its shareholders.
• Cash flows from continuing operating activities were $2.076 billion for the first nine months of fiscal year 2025, a decrease from $2.666 billion in the prior-year period, mainly due to higher inventory and lower accounts payable.
• The company repurchased $750 million of common stock in the first nine months of fiscal year 2025, and the Board authorized an additional 10 million shares for repurchase on January 28, 2025.
• Product liability accruals decreased to $1.5 billion at June 30, 2025, from $1.7 billion at September 30, 2024, reflecting settlement payments and legal fees.
• The company recorded a $114 million liability as of June 30, 2025, for estimated future costs related to addressing non-conformities cited in the FDA's Pyxis Dispensing Warning Letter, with net adjustments of $98 million recorded in the nine months ended June 30, 2025.
• The 2004 Employee and Director Equity-Based Compensation Plan and the Performance Incentive Plan were amended and restated effective July 22, 2025, introducing updated terms for equity awards and incentive payments, including clawback policies.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While Q3 financial performance showed strong revenue and operating income growth, the nine-month results reveal a decline in net income and EPS due to significant 'specified items' and higher interest expenses. The strategic spin-off is a positive long-term move, but ongoing legal and regulatory challenges, particularly the EtO litigation and FDA Warning Letter, introduce considerable uncertainty and financial liabilities. The cash flow from operations also decreased. The overall picture is one of strategic transformation with notable operational and legal headwinds.

Positives

• Strong revenue growth of 10.4% in Q3 2025, driven by volume, foreign currency impact, and the Advanced Patient Monitoring acquisition.
• Significant increase in operating income (46.5%) and net income (17.9%) for Q3 2025.
• Diluted EPS for Q3 2025 increased by 19.0% to $2.00.
• Strategic combination of Biosciences and Diagnostic Solutions business with Waters Corporation is expected to create an innovative life science and diagnostics leader and is structured to be generally tax-free for U.S. federal income tax purposes to BD and its shareholders.
• The company will receive a cash distribution of approximately $4 billion from the Waters transaction, enhancing liquidity.
• Continued return of value to shareholders through dividends, with $1.04 per common share paid in Q3 2025 and $3.12 for the nine-month period.
• Ongoing share repurchase program, with $750 million executed in the first nine months of fiscal year 2025 and an additional 10 million shares authorized for repurchase.
• Medical segment showed strong revenue growth (14.4% total, 14.0% FXN) in Q3 2025, driven by Vascular Access Management, infusion systems, dispensing solutions, and prefillable solutions.
• Interventional segment demonstrated robust revenue growth (7.2% total, 6.8% FXN) in Q3 2025, led by advanced tissue regeneration, peripheral vascular disease portfolio, and PureWick™ offerings.
• Operating performance in Q3 2025 showed higher gross profit margin due to lower manufacturing costs from continuous improvement projects and favorable product mix from the Advanced Patient Monitoring unit.

Negatives

• Net income for the nine months ended June 30, 2025, decreased by 9.2% compared to the prior-year period, primarily due to higher 'specified items' and increased interest expense.
• Diluted EPS for the nine months ended June 30, 2025, decreased by 8.7% compared to the prior-year period.
• Cash and equivalents significantly decreased to $735 million at June 30, 2025, from $1.717 billion at September 30, 2024.
• Net cash provided by operating activities decreased to $2.076 billion for the first nine months of fiscal year 2025 from $2.666 billion in the prior-year period, mainly due to higher inventory levels and lower accounts payable.
• Net cash flows from financing activities shifted to a significant use of cash ($2.808 billion) in the first nine months of fiscal year 2025, compared to a net inflow ($1.963 billion) in the prior-year period.
• Life Sciences segment experienced a slight revenue decline (0.5% total, 1.1% FXN) in Q3 2025, driven by lower sales of point-of-care products, BD BACTEC™ blood culture products, and Biosciences instruments.
• Higher interest expense for the three and nine-month periods of fiscal year 2025 reflected higher overall interest rates on outstanding debt.
• Lower interest income for the three and nine-month periods of fiscal year 2025 reflected lower cash on hand and lower overall interest rates.
• The effective income tax rate for Q3 2025 increased to 18.3% from 2.6% in Q3 2024, primarily due to an unfavorable tax impact from discrete items.
• The nine-month gross profit margin was unfavorably impacted by purchase accounting adjustments and other specified items, including a $336 million fair value step-up adjustment relating to Advanced Patient Monitoring's inventory.

Risks

• The proposed combination of the Biosciences and Diagnostic Solutions business with Waters Corporation may not be completed on the currently contemplated timeline or at all, potentially leading to significant non-recurring costs.
• The announcement and pendency of the Waters transaction could cause disruptions in business operations, divert management attention, and negatively impact relationships with customers and third parties.
• There is no assurance that the Waters transaction will qualify as tax-free for U.S. federal income tax purposes; if taxable, significant income tax liabilities could be incurred.
• The company is defending approximately 6,845 product liability claims related to hernia repair devices, with potential for significant settlements or charges in excess of accruals.
• Ongoing litigation related to ethylene oxide (EtO) sterilization activities in Covington, GA, including a recent jury award of $20 million in compensatory damages and a mistrial declared on a $50 million punitive damages finding, poses significant financial and reputational risk.
• The FDA issued a Warning Letter in November 2024 regarding the BD Pyxis™ Dispensing quality management system, with no assurances that corrective actions will be adequate or that further regulatory actions (e.g., seizure, injunction, civil monetary penalties) will not be initiated.
• The U.S. infusion pump business (BD Alaris™) operates under a Consent Decree with the FDA, which could lead to orders to cease manufacturing/distribution, product recalls, or significant monetary damages for future violations.
• Increased regulatory focus on ethylene oxide use and emissions by the EPA could lead to additional regulatory requirements, temporary suspension of operations, or increased costs for sterilization.
• Global macroeconomic factors, including market dynamics in China (e.g., volume-based procurement programs), reductions/delays in governmental research funding, and higher interest rates, could adversely impact demand and financial results.
• Temporary shortages in supply of certain materials or components, and disruptions in global transport, could adversely impact the supply chain and distribution channels.
• Tariffs, sanctions, or other trade barriers could increase supply chain costs and adversely impact results of operations and financial condition, with an estimated $90 million impact from tariffs expected in fiscal year 2025.
• The company faces risks related to its overall level of indebtedness and its ability to service and refinance debt, which is dependent on capital markets and the macroeconomic environment.
• IT system disruptions, breaches, or breakdowns, including cyberattacks, could impair business operations, result in loss of trade secrets or sensitive information, or lead to legal proceedings and reputational damage.

Future Outlook

The company's growth strategy is anchored in three pillars: grow, simplify, and empower, with continued investment in R&D, strategic acquisitions, geographic expansion, and new product programs. Future growth depends on expanding the core business, developing innovative products, and improving operating efficiency. The proposed combination of the Biosciences and Diagnostic Solutions business with Waters Corporation is expected to create an innovative life science and diagnostics leader. The company anticipates an estimated $90 million impact from tariffs to its fiscal year 2025 operating expense. The remediation and replacement of BD Alaris™ Infusion System devices in the U.S. market will continue over the next several years. The company is assessing the impact of new U.S. tax legislation (OBBB Act) but does not currently expect a material impact on fiscal year 2025 consolidated financial results.

Management Comments

• Our BD 2025 strategy for growth is anchored in three pillars: grow, simplify and empower.
• We continue to pursue growth opportunities in emerging markets.
• We continually evaluate various global macroeconomic factors and other risks to assess their potential impact to our operations and financial results.
• We believe that given our debt ratings, our financial management policies, our ability to generate cash flow and the non-cyclical, geographically diversified nature of our businesses, we would have access to additional short-term and long-term capital should the need arise.
• We believe the current reserves related to all governmental receivables are adequate and that these receivables will not have a material adverse impact on our financial position or liquidity.
• We do not believe that a loss is probable in connection with the Alaris™ Infusion Pumps Consent Decree, and accordingly, we have no accruals associated with compliance with the Consent Decree.
• We are assessing the impact of the Interim Registration Review Decision for Ethylene Oxide (ID) on our sterilization facilities, on the third-party sterilization facilities that BD utilizes and on our operations more generally.

Industry Context

The medical technology industry continues to face evolving challenges, including market dynamics in China (e.g., volume-based procurement), potential reductions in governmental research funding, and the impact of higher interest rates on capital purchases. Regulatory scrutiny, particularly from the FDA regarding quality systems and product compliance, remains a significant factor, as evidenced by the ongoing Alaris™ Consent Decree and the Pyxis™ Warning Letter. The increased focus on ethylene oxide sterilization by environmental agencies also highlights a broader industry challenge in maintaining critical sterilization processes while adhering to stricter environmental standards. BD's strategic move to spin off and combine its Biosciences and Diagnostic Solutions business with Waters Corporation reflects a trend towards specialization and creating focused entities to better compete in specific high-volume, regulated testing markets within the life sciences and diagnostics sectors. This move aims to unlock value and optimize resource allocation in a competitive landscape.

Comparison to Industry Standards

• The strategic combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation via a Reverse Morris Trust is a notable move, similar to other large healthcare and life science companies divesting non-core or specialized assets to create more focused entities. For example, Siemens Healthineers spun off its diagnostics unit, and GE Healthcare spun off from General Electric, aiming for greater agility and market focus.
• BD's Q3 2025 revenue growth of 10.4% is robust, especially considering the macroeconomic headwinds and specific market challenges like China's volume-based procurement programs. This growth rate compares favorably to some peers in the medical device sector that might be experiencing slower growth due to market saturation or increased competition.
• The decline in net income and EPS for the nine-month period, largely attributed to 'specified items' including acquisition-related adjustments and legal/remediation costs, indicates that while core operations may be performing, the company is absorbing significant one-time or non-recurring expenses. This is a common challenge for large, diversified companies undergoing strategic transformations and facing complex litigation, but it warrants close monitoring compared to companies with cleaner earnings profiles.
• The ongoing legal proceedings, particularly the hernia mesh and EtO litigation, are significant and represent a higher level of legal exposure compared to some industry peers. While the company maintains meritorious defenses, the scale and nature of these mass torts are comparable to those faced by other large medical device manufacturers like Johnson & Johnson (pelvic mesh) or Boston Scientific (pelvic mesh), which have resulted in substantial settlements.
• The FDA Warning Letter for Pyxis™ dispensing equipment and the ongoing Alaris™ Consent Decree highlight persistent regulatory compliance challenges. While regulatory issues are inherent in the medical device industry, the duration and scope of these issues for BD are more pronounced than for companies with fewer legacy product lines or a more streamlined regulatory history, such as newer, more specialized medtech firms.

Corporate Governance

Legal Proceedings

• Approximately 6,845 product liability claims involving hernia repair devices are being defended, with the majority pending in Rhode Island State Court and a federal multi-district litigation in the Southern District of Ohio, plus multiple putative class actions in Canada.
• Ongoing defense against product liability claims related to pelvic mesh products, inferior vena cava (IVC) filter products, and implantable ports.
• A putative shareholder derivative action, Jankowski v. Forlenza, et al., has an agreement in principle to resolve for $9 million, with preliminary court approval on June 9, 2025, and a final approval hearing set for August 11, 2025.
• Civil Investigative Demands (CIDs) from the Department of Justice are ongoing, seeking information related to: (i) sales and marketing of FloChec and QuantaFlo™ devices (since July 2017), (ii) CareFusion's contracts with the Department of Veterans Affairs for Alaris™ and Pyxis™ devices (since April 2019), and (iii) Genesis™ container products (since April 2023).
• Approximately 390 lawsuits involving about 400 plaintiffs are pending in Georgia state courts related to ethylene oxide (EtO) sterilization activities at the Covington, GA facility, alleging various injuries including cancer.
• On May 2, 2025, a jury in the first Covington, GA EtO trial awarded the plaintiff $20 million in compensatory damages; on May 6, 2025, a $50 million punitive damages finding was made but a mistrial was declared on this phase due to non-unanimous specific intent finding, with no judgment entered yet.
• Litigation proceedings are still pending in Italy regarding the medical device payback legislation, despite the Italian Constitutional Court ruling it constitutional in July 2024; the company has accrued $62 million for this matter.
• The company received a Warning Letter from the FDA on November 22, 2024, concerning its BD Pyxis™ Dispensing quality management system, citing alleged violations of quality system, MDR, and corrections/removals regulations, leading to a $114 million liability accrual for remediation efforts.
• The U.S. infusion pump organizational unit continues to operate under an amended consent decree with the FDA (originally 2007, amended 2009) related to Alaris™ infusion pumps, with a letter of non-compliance issued in December 2021; no loss is currently deemed probable, and no accruals are associated with compliance with the decree.

Stakeholder Impact

• Shareholders: Potential for value creation through the spin-off of Biosciences and Diagnostic Solutions, continued dividends, and share repurchases. However, the decline in nine-month EPS and ongoing legal/regulatory risks could impact shareholder value.
• Employees and Directors: Equity-based compensation and performance incentive plans are designed to align interests with company performance and shareholder value, with new clawback policies reinforcing accountability.
• Customers: Ongoing product remediation efforts (e.g., Alaris™ Infusion System, Pyxis™ dispensing equipment) aim to improve product quality and customer experience, but regulatory issues could lead to disruptions or limitations on product availability.
• Suppliers: Supply chain disruptions, including those related to raw materials (e.g., oil-based resins) and sterilization services (e.g., ethylene oxide), could impact the company's ability to manufacture products, potentially affecting supplier relationships and demand.
• Creditors: The company's debt levels and ability to service debt are subject to capital market conditions and macroeconomic factors, which could affect borrowing costs and access to capital.
• Regulatory Authorities: The company faces significant scrutiny from the FDA and EPA, with ongoing consent decrees, warning letters, and environmental regulations requiring substantial compliance efforts and potential liabilities.

Next Steps

• Final approval hearing for the Jankowski v. Forlenza, et al. settlement scheduled for August 11, 2025.
• Continue to assess and implement corrective actions in response to the FDA's Pyxis™ Dispensing Warning Letter.
• Continue to work with the FDA to generate additional clinical evidence and file 510(k)s as remaining commitments associated with the former BD Preanalytical Systems Warning Letter.
• Continue to implement changes at ethylene oxide sterilization facilities in accordance with revised NESHAP requirements and the EPA's Interim Registration Review Decision for Ethylene Oxide.
• The proposed combination of the Biosciences and Diagnostic Solutions business with Waters Corporation is expected to close around the end of the first quarter of calendar year 2026, subject to regulatory and shareholder approvals and other closing conditions.
• BD will incorporate Advanced Patient Monitoring into its annual assessment of internal control over financial reporting for its fiscal year ending September 30, 2025.

Key Dates

Recommendation

The company presents a mixed financial picture. While Q3 2025 showed strong revenue and operating income growth, the nine-month results indicate a decline in net income and EPS, largely due to significant 'specified items' and increased interest expenses. The strategic spin-off of the Biosciences and Diagnostic Solutions business is a major positive catalyst, potentially unlocking value and streamlining operations. However, the company faces substantial ongoing legal and regulatory challenges, particularly the hernia mesh and EtO litigations, and FDA warning letters, which introduce considerable uncertainty and potential liabilities. The decrease in cash flow from operations also warrants attention. Given the balance of strategic upside from the spin-off against the backdrop of complex and costly legal/regulatory headwinds, a 'hold' recommendation is appropriate. Investors should monitor the progress of the spin-off, the resolution of legal matters, and the impact of regulatory compliance efforts on future financial performance.

Keywords

Medical Technology, SEC Filing, Quarterly Report, BDX, Becton Dickinson, Financial Results, Revenue Growth, Earnings Per Share, Strategic Spin-off, Waters Corporation, Biosciences, Diagnostic Solutions, Medical Devices, Pharmaceutical Systems, Advanced Patient Monitoring, Litigation, Product Liability, FDA Warning Letter, Ethylene Oxide, Share Repurchase, Cash Flow, Debt Management, Corporate Governance, Compensation Plan